Biomx Inc Financials
This page shows Biomx Inc (PHGE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BiomX remains a research-led cash burner, but FY2025 shows the financing cushion has largely run out.
Operating cash burn stayed close to-$21.3M in FY2023 and-$26.4M in FY2025, so the core spending pace did not really reset. What changed was funding capacity: cash fell to$4.4M and equity to-$1.3M in FY2025, so similar burn is now landing on a balance sheet that no longer carries its own buffer.
Cash conversion is unusually direct in a negative sense: FY2025 operating cash flow of
The cost base is still centered on research, with R&D at
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Biomx Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Biomx Inc carries a low D/E ratio of -5.44, meaning only $-5.44 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.
Biomx Inc's current ratio of 0.87 is below the typical benchmark, resulting in a score of 12/100. However, the company holds substantial cash reserves (68% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
Key Financial Metrics
Earnings & Revenue
Biomx Inc earned $22.19 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 61.9% from the prior year.
Cash & Balance Sheet
Biomx Inc generated -$26.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 28.7% from the prior year.
Biomx Inc held $4.4M in cash against $0 in long-term debt as of fiscal year 2025.
Biomx Inc had 2M shares outstanding in fiscal year 2025. This represents an increase of 55.8% from the prior year.
Margins & Returns
Capital Allocation
Biomx Inc invested $21.3M in research and development in fiscal year 2025. This represents a decrease of 13.7% from the prior year.
Biomx Inc invested $2K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 93.3% from the prior year.
PHGE Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | $6.1M+22.1% | $5.0M-4.5% | $5.3M | N/A | $7.3M+5.5% | $6.9M |
| SG&A Expenses | $1.6M | N/A | $2.4M-0.2% | $2.4M-3.5% | $2.5M | N/A | $3.2M+14.9% | $2.8M |
| Operating Income | -$1.3M | N/A | -$8.5M-14.8% | -$7.4M+4.2% | -$7.8M | N/A | -$11.3M-16.5% | -$9.7M |
| Interest Expense | $192K | N/A | $5K0.0% | $5K-99.4% | $850K | N/A | $5K-99.4% | $850K |
| Income Tax | N/A | N/A | $3K+50.0% | $2K+100.0% | $1K | N/A | N/A | $5K |
| Net Income | N/A | N/A | -$9.2M-51.8% | -$6.0M+21.2% | -$7.7M | N/A | $9.6M+115.7% | $4.5M |
| EPS (Diluted) | $7.38 | N/A | $0.29+52.6% | $0.19-97.0% | $6.27 | N/A | $-0.31 | $0.69 |
PHGE Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.3M-43.8% | $5.8M-77.9% | $26.2M-31.2% | $38.0M-16.7% | $45.7M+5.6% | $43.2M-27.9% | $60.0M-12.6% | $68.6M |
| Current Assets | $3.0M-45.4% | $5.6M-37.1% | $8.9M-46.7% | $16.6M-29.3% | $23.5M+14.7% | $20.5M-27.5% | $28.3M-19.3% | $35.1M |
| Cash & Equivalents | $1.2M-73.2% | $4.4M-37.0% | $6.9M-50.7% | $14.0M-30.2% | $20.1M+19.3% | $16.9M-28.4% | $23.5M-25.5% | $31.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | $801K0.0% | $801K-94.9% | $15.8M |
| Total Liabilities | $4.1M-41.7% | $7.1M-54.8% | $15.7M-17.0% | $18.9M-10.7% | $21.2M+10.8% | $19.1M-13.6% | $22.1M-46.4% | $41.2M |
| Current Liabilities | $2.4M-61.6% | $6.4M+22.1% | $5.2M-16.5% | $6.3M-10.8% | $7.0M-15.1% | $8.3M-7.6% | $8.9M+22.4% | $7.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$881K+32.3% | -$1.3M-112.4% | $10.5M-45.3% | $19.2M-21.8% | $24.5M+1.5% | $24.1M-36.3% | $37.9M+38.2% | $27.4M |
| Retained Earnings | -$236.0M-8.8% | -$216.9M-6.6% | -$203.6M-4.7% | -$194.4M-3.2% | -$188.4M-4.2% | -$180.7M-8.7% | -$166.2M+5.5% | -$175.8M |
PHGE Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.4M-23.4% | -$4.4M+38.9% | -$7.2M-17.6% | -$6.1M+29.9% | -$8.7M-38.5% | -$6.3M+22.3% | -$8.1M+27.9% | -$11.2M |
| Capital Expenditures | N/A | $0 | N/A | N/A | N/A | $11K+10.0% | $10K | N/A |
| Free Cash Flow | N/A | -$4.4M | N/A | N/A | N/A | -$6.3M+22.3% | -$8.1M | N/A |
| Investing Cash Flow | -$996K-99700.0% | $1K+150.0% | -$2K-103.4% | $58K+13.7% | $51K+5200.0% | -$1K0.0% | -$1K-101.9% | $54K |
| Financing Cash Flow | $2.6M+109.7% | $1.3M+2216.7% | $54K+286.2% | -$29K-100.2% | $11.9M+3093.2% | -$398K | $0+100.0% | -$203K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PHGE Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | -87.4%-55.9pp | -31.5%-0.3pp | -31.3% | N/A | 25.4%+9.1pp | 16.3% |
| Return on Assets | N/A | N/A | -35.0%-19.2pp | -15.9%+0.9pp | -16.8% | N/A | 16.1%+9.6pp | 6.5% |
| Current Ratio | 1.24+0.4 | 0.87-0.8 | 1.70-1.0 | 2.66-0.7 | 3.35+0.9 | 2.48-0.7 | 3.17-1.6 | 4.80 |
| Debt-to-Equity | -4.69+0.8 | -5.44-6.9 | 1.50+0.5 | 0.99+0.1 | 0.86+0.1 | 0.79+0.2 | 0.58-0.9 | 1.50 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.87), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Biomx Inc's free cash flow?
Biomx Inc (PHGE) generated -$26.4M in free cash flow during fiscal year 2025. This represents a 28.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biomx Inc's operating cash flow?
Biomx Inc (PHGE) generated -$26.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Biomx Inc's total assets?
Biomx Inc (PHGE) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Biomx Inc's capital expenditures?
Biomx Inc (PHGE) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Biomx Inc spend on research and development?
Biomx Inc (PHGE) invested $21.3M in research and development during fiscal year 2025.
What is Biomx Inc's current ratio?
Biomx Inc (PHGE) had a current ratio of 0.87 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Biomx Inc's debt-to-equity ratio?
Biomx Inc (PHGE) had a debt-to-equity ratio of -5.44 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biomx Inc's cash runway?
Based on fiscal year 2025 data, Biomx Inc (PHGE) had $4.4M in cash against an annual operating cash burn of $26.4M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Biomx Inc's debt-to-equity ratio negative or unusual?
Biomx Inc (PHGE) has negative shareholder equity of -$1.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
How financially healthy is Biomx Inc?
Biomx Inc (PHGE) scores 16 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.